Farzaneh Khademi - Department of tissue engineering and applied cell sciences, School of advanced technologies and Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

IntroductionCell-based therapy is a promising option for treatment of cardiac diseases like ischemic heart disease. Despite increasing the LVEF and decreasing the size of the myocardial infarcted area in earlier studies of autologous stem cells transplantation, but the autologous therapy is accompanied with some limitation such as timeframe of treatment, tissue harvesting and cell processing. Allogeneic stem cells from young healthy donors can be produced in large quantities and be immediately available as a product for urgent therapy, including acute myocardial infarction.ObjectiveMany reports highlight the immunomedullary properties of some stem cells, like MSCs, but a study on the use of stem cells from different sources to evaluate whether immune modulation is a common stem cell characteristic is still missing.Methods & ResultsStandard methods for assessing the immunity and immunogenicity of stem cells and their comparison based on the stimulation of immune cells have been introduced. Recent animal studies and phase 1/2 clinical trials have shown that mesenchymal stem cells and cardiac stem cells have very promising results, which in part can be attributed to their attractive immunomedullary properties.ConclusionThe allogeneic cells have been shown the modulation of immune response by secreting cytokine factors. However, recent studies have shown evidence of their immunity. Long-term follow-up studies are needed to confirm the safety of allogeneic stem cells

Cardiac diseases, Cell therapy, Allogeneic stem cells, Immunogenicity